ENA-001 is under clinical development by Enalare Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

The devices remain unreliable in darker skinned people. Researchers say more guidance, enforcement and even legal action may ...

In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.

Oxygen therapy saves lives, but does it improve quality of life? Dr Holley explores the balance of benefits, burdens, and ...